PB-207

PB-207 is a preclinical-stage small molecule drug candidate developed by Pan-Biome Pharmaceuticals. It is part of the company's pipeline focused on treating chronic inflammatory diseases and potentially extending human healthspan and lifespan. Pan-Biome's therapeutic approach involves the modulation of the 'Pan-Biome,' which refers to the complex interface between the gut microbiome and the host's immune system. While the specific molecular targets for PB-207 have not been publicly detailed, the company's platform emphasizes the development of multi-cytokine inhibitors that regulate pathways involving TNF-alpha, IL-1, and IL-6 to address systemic inflammation associated with aging and chronic disease.